{
  "description": "AI Canteen — longevity-research 专题索引",
  "copyright": "© 2026 Hanya Advisory",
  "last_updated": "2026-05-06T09:33:37.192624+08:00",
  "total": 15,
  "feeds": [
    {
      "id": "longevity-research_20260506_0001_表观遗传重编程进入人体临床试验",
      "title": "表观遗传重编程进入人体临床试验",
      "url": "/posts/longevity-research/20260506_0001_表观遗传重编程进入人体临床试验.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "Life Biosciences（哈佛David Sinclair联合创立）的ER-100基因疗法获FDA批准开展人体试验，是全球首个部分细胞重编程人体临床试验。使用3种山中因子（Oct4、Sox2、Klf4，排除致癌风险高的c-Myc），...",
      "tags": [
        "重编程",
        "人体试验",
        "FDA"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0002_雷帕霉素人体数据_效果好坏参半",
      "title": "雷帕霉素人体数据：效果好坏参半",
      "url": "/posts/longevity-research/20260506_0002_雷帕霉素人体数据_效果好坏参半.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "PEARL试验：低剂量间歇雷帕霉素安全且耐受良好。女性10mg/周获益显著：瘦体重↑、生活质量↑、骨关节炎评分改善；男性骨矿物质含量↑。但未显著减少内脏脂肪。RAPA-EX-01试验：雷帕霉素+运动在老年人中未增强运动效果，反而轻微削弱。V...",
      "tags": [
        "雷帕霉素",
        "临床试验",
        "PEARL"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0003_NMN_NAD_临床证据持续累积",
      "title": "NMN/NAD+临床证据持续累积",
      "url": "/posts/longevity-research/20260506_0003_NMN_NAD_临床证据持续累积.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "12项以上人体试验已完成，剂量100-1250mg/天安全。2026年1月研究：NMN与NR补充14天后循环NAD+水平翻倍。多项RCT显示改善步行速度、握力、有氧能力、胰岛素敏感性。FDA在2025年明确NMN的膳食补充剂地位。趋势从能不...",
      "tags": [
        "NMN",
        "NAD+",
        "临床试验"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0004_Senolytics从泛抗衰老转向精准疾病",
      "title": "Senolytics从泛抗衰老转向精准疾病",
      "url": "/posts/longevity-research/20260506_0004_Senolytics从泛抗衰老转向精准疾病.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "D+Q（达沙替尼+槲皮素）：2026年进一步证实改善肾功能、减少SASP因子、改善肺纤维化患者身体功能。RLS-1496（Rubedo Life Sciences）：靶向皮肤衰老的外用senolytic，已进入I期临床。方向从抗衰老宽泛声称...",
      "tags": [
        "Senolytics",
        "衰老细胞",
        "精准医学"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0005_热量限制_vs_间歇性禁食",
      "title": "热量限制 vs 间歇性禁食",
      "url": "/posts/longevity-research/20260506_0005_热量限制_vs_间歇性禁食.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "Nature研究显示热量限制对延长寿命的效果优于间歇性禁食。关键发现：体重不降的小鼠反而活得更长，挑战了减重=长寿的传统认知。Nutrients汇总31项研究：适度禁食可帮助老年人减重且不流失肌肉。但每天禁食>14小时或连续数天禁食对60岁...",
      "tags": [
        "热量限制",
        "禁食",
        "饮食干预"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0006_胸腺被重新发现为衰老调节器",
      "title": "胸腺被重新发现为衰老调节器",
      "url": "/posts/longevity-research/20260506_0006_胸腺被重新发现为衰老调节器.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "胸腺这一常被忽视的器官正在被重新定义为衰老的强力调节器。胸腺健康者肺癌、心脏病死亡和全因死亡率更低，对免疫治疗药物应答也更佳。...",
      "tags": [
        "胸腺",
        "免疫",
        "衰老"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0007_AI驱动长寿药物发现",
      "title": "AI驱动长寿药物发现",
      "url": "/posts/longevity-research/20260506_0007_AI驱动长寿药物发现.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "AI生成的候选药物在部分研究中显示出70%的寿命延长成功率。AI正在被用于个性化健康管理、实时监测和动态长寿管理。...",
      "tags": [
        "AI",
        "药物发现",
        "长寿科技"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260506_0008_旅行抗衰老_ECU新理论",
      "title": "旅行抗衰老：ECU新理论",
      "url": "/posts/longevity-research/20260506_0008_旅行抗衰老_ECU新理论.txt",
      "date": "2026-05-06T06:00:00+08:00",
      "summary": "澳大利亚埃迪斯科文大学提出：积极旅行体验通过新环境刺激、增加运动、社交互动和积极情绪，可能帮助维持身体的低熵状态，从代谢、免疫、神经内分泌四个系统层面减缓衰老。...",
      "tags": [
        "旅行",
        "抗衰老",
        "ECU"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0001_细胞重编程首次进入人体试验",
      "title": "细胞重编程首次进入人体试验",
      "url": "/posts/longevity-research/20260505_0001_细胞重编程首次进入人体试验.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "基于Yamanaka因子的部分细胞重编程技术获FDA批准进入首个人体临床试验。Altos Labs等机构投入巨资，致力于将细胞逆向恢复至健康状态。这标志着逆转衰老从理论走向临床实践。...",
      "tags": [
        "重编程",
        "人体试验",
        "里程碑"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0002_VITAL_H试验启动_三大药物同时评估",
      "title": "VITAL-H试验启动：三大药物同时评估",
      "url": "/posts/longevity-research/20260505_0002_VITAL_H试验启动_三大药物同时评估.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "耗资3800万美元的全国性试验VITAL-H由UT Health San Antonio主导，评估雷帕霉素、司美格鲁肽和达格列净能否延缓700多名60岁以上成人的生物学衰老。...",
      "tags": [
        "VITAL-H",
        "雷帕霉素",
        "司美格鲁肽"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0003_雷帕霉素人体数据出炉",
      "title": "雷帕霉素人体数据出炉",
      "url": "/posts/longevity-research/20260505_0003_雷帕霉素人体数据出炉.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "RAPA-EX-01试验：每周西罗莫司联合运动，雷帕霉素未增强运动功能增益。PEARL试验：114名50-85岁参与者一年低剂量间歇雷帕霉素，总体安全可耐受。女性组观察到肌肉量增加和疼痛减轻。结论：人体证据仍有限。...",
      "tags": [
        "雷帕霉素",
        "RAPA-EX-01",
        "PEARL"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0004_Senolytics管道进展",
      "title": "Senolytics管道进展",
      "url": "/posts/longevity-research/20260505_0004_Senolytics管道进展.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "D+Q在特发性肺纤维化和糖尿病肾病中有初步积极信号。SToMP-AD试验II期多中心RCT评估senolytics在阿尔茨海默病早期患者中的效果。Fisetin在AFFIRM-LITE试验中日均2000mg耐受性良好。Nature Agin...",
      "tags": [
        "Senolytics",
        "D+Q",
        "Fisetin"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0005_NAD_人体研究_NMN14天翻倍",
      "title": "NAD+人体研究：NMN14天翻倍",
      "url": "/posts/longevity-research/20260505_0005_NAD_人体研究_NMN14天翻倍.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "NMN补充14天后血NAD+水平约翻倍。一项还原型NMN首个人体试验：每日500mg连续90天，报告生物学年龄平均减少5岁（待同行评审）。改善握力、步行速度、有氧能力、胰岛素敏感性的数据持续累积。...",
      "tags": [
        "NMN",
        "NAD+",
        "人体试验"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0006_热量限制减炎机制被揭示",
      "title": "热量限制减炎机制被揭示",
      "url": "/posts/longevity-research/20260505_0006_热量限制减炎机制被揭示.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "耶鲁医学院在Nature Aging发文：中等程度热量限制（减少11-14%）可显著降低与衰老相关的炎症，发现免疫蛋白C3的下降是关键机制，且独立于体重减轻。...",
      "tags": [
        "热量限制",
        "炎症",
        "C3蛋白"
      ],
      "category": "longevity-research",
      "type": "research"
    },
    {
      "id": "longevity-research_20260505_0007_百岁老人启示录",
      "title": "百岁老人启示录",
      "url": "/posts/longevity-research/20260505_0007_百岁老人启示录.txt",
      "date": "2026-05-05T06:00:00+08:00",
      "summary": "系统综述：植物性饮食、规律运动、冥想练习与低压力反应相关。百岁老人共同特征：持续生活意愿、弹性应对损失、强社会联系、自主权、对生死豁达。哈佛成人发展研究：社交满意度是预防80岁失智和病痛的最强预测因子。...",
      "tags": [
        "百岁老人",
        "生活方式",
        "社交"
      ],
      "category": "longevity-research",
      "type": "research"
    }
  ]
}